Skip to search formSkip to main contentSkip to account menu

RSR 13

Known as: RSR-13, RSR13, RSR13 cpd 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

efaproxiral

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
PURPOSE Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases tissue pO2. We… 
2004
2004
Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
2004
2004
Efaproxiral: a novel radiation sensitiser
Efaproxiral (RSR13) is a synthetic allosteric modifier of haemoglobin that reduces its oxygen binding affinity. By facilitating… 
2002
2002
Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.
Reducing the hemolobin (Hb)-O(2) binding affinity facilitates O(2) unloading from Hb, potentially increasing tissue mitochondrial… 
2001
2001
Enhancement of Tumor Oxygenation and Radiation Response by the Allosteric Effector of Hemoglobin, RSR13
Abstract Amorino, G. P., Lee, H., Holburn, G. E., Paschal, C. B., Hercules, S. K., Shyr, Y., Steffen, R. P. and Choy, H… 
2001
2001
Allosteric Modification of Oxygen Delivery by Hemoglobin
Hemoglobin affinity for oxygen is altered by pH, temperature, and high altitude, making oxygen more readily available to the… 
1999
1999
Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
PURPOSE To determine the safety, pharmacokinetics, and pharmacodynamic effect of 2-[4-(3, 5-dimethylanilino)carbonyl]methyl… 
1999
1999
RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermic cardiopulmonary bypass.
BACKGROUND During hypothermic blood cardioplegia, oxygen delivery to myocytes is minimal with ineffective anaerobic metabolism… 
1998
1998
RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
RSR13, 2[4-[[(3,5dimethylanilino)carbonyl]methyl]phenoxy]-2-methylpropion ic acid, a synthetic allosteric modifier of hemoglobin… 
1996
1996
RSR13: Effects on tumor oxygenation and response to therapy
RSR13,[2,4‐[[(3,5‐dimethylanilino) carbonyl]methyl]phenoxy]‐2‐methylpropionic acid], is a new allosteric effector of hemoglobin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)